TherapeuticsMD (TXMD) Receiving Somewhat Favorable Media Coverage, Report Finds
Media coverage about TherapeuticsMD (NASDAQ:TXMD) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.7744468194785 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- TherapeuticsMD (TXMD) Receives Buy Rating from Oppenheimer (americanbankingnews.com)
- In Play Stock Characteristics – TherapeuticsMD Inc (NASDAQ: TXMD) – Alpha Beta Stock (alphabetastock.com)
- Quotidian Technical Highlights on Selected Drug Makers Stocks — Sanofi, Shire, TherapeuticsMD, and Zogenix (bizjournals.com)
- TherapeuticsMD, Inc. (TXMD) : Investors watching Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- TherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA Date (finance.yahoo.com)
TXMD has been the topic of a number of research reports. BidaskClub cut TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 31st. Oppenheimer reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, December 20th. Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 price target on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Finally, Deutsche Bank set a $9.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $4.66 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The firm’s revenue for the quarter was down 8.0% compared to the same quarter last year. research analysts expect that TherapeuticsMD will post -0.38 EPS for the current year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.